Correspondence 0001104659-23-112547 from AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963) (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963)
Date: Oct. 30, 2023 · CIK: 0001644963 · Accession: 0001104659-23-112547
AI Filing Summary & Sentiment
File numbers found in text: 333-274562
Letter
Avenue Therapeutics, Inc.
1111 Kane Concourse, Suite 301
Bay Harbor Islands, Florida 33154
VIA EDGAR
October 30, 2023
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Joshua Gorsky
Re:
Avenue Therapeutics, Inc.
Registration Statement on Form S-1 (Reg. No. 333-274562)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Avenue Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended, the “Registration Statement”) so that the Registration Statement will be declared effective as of 9:00 a.m. Eastern time, on October 31, 2023, or as soon as practicable thereafter. The Company hereby authorizes Rakesh Gopalan or David Wolpa, both of whom are attorneys at the Company’s outside legal counsel, McGuireWoods LLP, to orally modify or withdraw this request for acceleration.
Once the Registration Statement has been declared effective, please orally confirm that event with Mr. Gopalan at (704) 343-2275 or Mr. Wolpa at (704) 343-2185.
Thank you for your assistance in this matter.
Very truly yours,
Avenue Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Avenue Therapeutics, Inc.
1111 Kane Concourse, Suite 301
Bay Harbor Islands, Florida 33154
VIA EDGAR
October 30, 2023
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Joshua Gorsky
Re:
Avenue Therapeutics, Inc.
Registration Statement on Form S-1 (Reg. No.
333-274562)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under
the Securities Act of 1933, as amended, Avenue Therapeutics, Inc. (the “Company”) hereby requests that the Securities
and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement
on Form S-1 (as amended, the “Registration Statement”) so that the Registration Statement will be declared effective
as of 9:00 a.m. Eastern time, on October 31, 2023, or as soon as practicable thereafter. The Company hereby authorizes Rakesh Gopalan
or David Wolpa, both of whom are attorneys at the Company’s outside legal counsel, McGuireWoods LLP, to orally modify or withdraw
this request for acceleration.
Once the Registration Statement
has been declared effective, please orally confirm that event with Mr. Gopalan at (704) 343-2275 or Mr. Wolpa at (704) 343-2185.
Thank you for your assistance
in this matter.
Very truly yours,
Avenue Therapeutics, Inc.
/s/ Alexandra MacLean
Name:
Alexandra MacLean
Title:
Chief Executive Officer
cc (via email):
Rakesh Gopalan and David Wolpa, McGuireWoods LLP
Barry Grossman, Sarah Williams, Matthew Bernstein, Ellenoff Grossman & Schole LLP
Eric Cheng, Maxim Group LLC